Barr Gains European Foothold Through $2.2 Bil. Pliva Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Pliva’s supervisory board accepts Barr’s bid despite several rivals vying for the Croatian generics firm.
You may also be interested in...
Teva/Barr Combination Creates Biosimilar Force
Teva’s $7.46 billion acquisition of Barr will result in a generics powerhouse, expanding U.S. leadership and geographic footprint.
Teva/Barr Combination Creates Biosimilar Force
Teva’s $7.46 billion acquisition of Barr will result in a generics powerhouse, expanding U.S. leadership and geographic footprint.
Actavis Raises Bid For Pliva; Will Barr Follow?
Actavis has increased its bid for the Croatian generic drug maker to roughly $2.5 bil., trumping Barr's $2.3 bil. offer.